Bio-Gene Technology Ltd (BGT) — Capital Reinvestment Ratio
Latest as of June 2022:
0.16x
Bio-Gene Technology Ltd (BGT) has a Capital Reinvestment Ratio of 0.16x as of June 2022, meaning it reinvests 0% of its operating cash flow (AU$43.52K) in capital expenditures (AU$6.84K). See BGT FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.16x
Capex / Operating Cash Flow
Operating Cash Flow
AU$43.52K
AUD
Capital Expenditures
AU$6.84K
AUD
Data as of
Jun 2022
Most recent filing
Bio-Gene Technology Ltd Capital Reinvestment Ratio (2022–2022)
This chart tracks Bio-Gene Technology Ltd's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Bio-Gene Technology Ltd (2022–2022)
Year-by-year Capital Reinvestment Ratio for Bio-Gene Technology Ltd from 2022 to 2022. For live market cap and broader valuation context, see Bio-Gene Technology Ltd (BGT) total market value.
| Year | Reinvestment Ratio | Operating CF (AUD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.16x | AU$43.52K | AU$6.84K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow